Quantitative proteomics analysis demonstrated T89 improved metabolic disorders by regulating expression of Eno1, Mcee, Bdh1, Ces1c, Apoc2, Decr1, Acaa2, Cbr4, ND2, Cox6a, Cox17, ATP5g, and ATP5j, further restoring mitochondrial ETC complex activities and attenuating ISO-caused oxidative stress damage and energy depletion. Here, COX17 is linked to metabolic disease.